FY2017 EPS Estimates for Collegium Pharmaceutical, Inc. Raised by Gabelli (COLL)

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) – Equities researchers at Gabelli upped their FY2017 earnings per share (EPS) estimates for shares of Collegium Pharmaceutical in a research note issued to investors on Thursday. Gabelli analyst K. Kedra now forecasts that the specialty pharmaceutical company will post earnings of ($2.45) per share for the year, up from their previous forecast of ($2.90). Gabelli also issued estimates for Collegium Pharmaceutical’s FY2018 earnings at ($1.65) EPS, FY2019 earnings at ($0.60) EPS, FY2020 earnings at $1.15 EPS and FY2021 earnings at $2.35 EPS.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.73) by $0.28. Collegium Pharmaceutical had a negative return on equity of 77.11% and a negative net margin of 447.83%. The firm had revenue of $11.95 million for the quarter, compared to analyst estimates of $5.31 million. During the same quarter in the prior year, the company posted ($1.13) earnings per share. Collegium Pharmaceutical’s quarterly revenue was up 2814.6% on a year-over-year basis.

ILLEGAL ACTIVITY WARNING: This story was originally published by Transcript Daily and is owned by of Transcript Daily. If you are viewing this story on another domain, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this story can be accessed at https://transcriptdaily.com/2017/11/15/fy2017-eps-estimates-for-collegium-pharmaceutical-inc-raised-by-gabelli-coll.html.

A number of other research analysts have also weighed in on COLL. Piper Jaffray Companies set a $14.00 price objective on Collegium Pharmaceutical and gave the stock a “buy” rating in a report on Tuesday, July 25th. BidaskClub lowered Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a report on Friday, August 4th. Zacks Investment Research raised Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a report on Monday, August 14th. HC Wainwright began coverage on Collegium Pharmaceutical in a report on Monday, September 11th. They issued a “buy” rating and a $21.00 target price on the stock. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $15.00 target price on shares of Collegium Pharmaceutical in a report on Thursday, September 21st. Two investment analysts have rated the stock with a sell rating and six have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $19.33.

Collegium Pharmaceutical (NASDAQ COLL) opened at $14.16 on Monday. Collegium Pharmaceutical has a twelve month low of $7.37 and a twelve month high of $17.73.

Institutional investors have recently bought and sold shares of the business. American International Group Inc. grew its holdings in Collegium Pharmaceutical by 27.8% in the first quarter. American International Group Inc. now owns 9,948 shares of the specialty pharmaceutical company’s stock valued at $100,000 after purchasing an additional 2,163 shares during the last quarter. Voya Investment Management LLC acquired a new stake in Collegium Pharmaceutical in the second quarter valued at $125,000. Nationwide Fund Advisors grew its holdings in Collegium Pharmaceutical by 16.4% in the first quarter. Nationwide Fund Advisors now owns 10,087 shares of the specialty pharmaceutical company’s stock valued at $101,000 after purchasing an additional 1,422 shares during the last quarter. Credit Suisse AG grew its holdings in Collegium Pharmaceutical by 9.4% in the first quarter. Credit Suisse AG now owns 13,630 shares of the specialty pharmaceutical company’s stock valued at $137,000 after purchasing an additional 1,173 shares during the last quarter. Finally, UBS Group AG grew its holdings in Collegium Pharmaceutical by 283.2% in the first quarter. UBS Group AG now owns 13,767 shares of the specialty pharmaceutical company’s stock valued at $139,000 after purchasing an additional 10,174 shares during the last quarter. 83.96% of the stock is currently owned by institutional investors.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Earnings History and Estimates for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply